Biocryst Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-15.9%projected annual EPS growth
Analyst Coverage
11analysts covering
FY EPS (est.)
$0.75next fiscal year
Monitoring Framework
Key Performance Indicators
ORLADEYO Global Net Revenue Quarterly148.3MTarget: $625 million to $645 million
Total Revenue (including RAPIVAB) Quarterly156.4M
Non-GAAP Operating Expenses Annually
Non-GAAP Operating Profit Quarterly
Watch Items
- ORLADEYO Pediatric Manufacturing DelayTrigger: Resolution of the pediatric manufacturing delayAction: Monitor resolution of the pediatric manufacturing delay to ensure full-year ORLADEYO revenue guidance is met.
- Navenibart Clinical DevelopmentTrigger: Completion of patient enrollment in ALPHA-ORBIT study by June 2026 and regulatory filing in the US by the end of 2027.Action: Track enrollment progress in the ALPHA-ORBIT study and progress toward US regulatory filing by the end of 2027.
Research as of 20 Jun 2026